Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Cencora is set to invest $1bn by 2030 to expand its US pharmaceutical distribution network, adding resilience and capacity.

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Leukogene Therapeutics has received orphan drug designation from the US FDA for M2T-CD33 (LTI-214), its immunotherapy candidate targeting AML.

The guidance change marks the latest adjustment Novo has made to its 2025 outlook as the company battles a changing market.

Here are three important regulatory changes affecting parenteral packaging that pharmaceutical companies need to be aware of ...

Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes ...

ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

Agentic AI was a point of emphasis on the first day of the 2025 Veeva Commercial summit held in Madrid, Spain.

The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...